#United States #Cranbury #Porton Advanced #Stem Cell Exosomes #INCI Status

Porton Advanced's Stem Cell Exosomes Achieve INCI Status

In a significant advancement for the cosmetic ingredient sector, Porton Advanced has proudly announced that its unique stem cell-derived exosomes have received official listing under the International Nomenclature of Cosmetic Ingredients (INCI). This official recognition serves as a global identification credential for cosmetic substances, marking a pivotal step in the company's efforts to integrate into the worldwide beauty market.

The INCI system, developed by the International Nomenclature Committee and published by the Personal Care Products Council, provides a universally recognized naming standard for cosmetic ingredients. Currently, it incorporates more than 16,000 ingredients and is employed by over 70 countries and regions, including major markets such as the United States, China, and the European Union. This wide acceptance highlights the global relevance of Porton Advanced's offerings.

Achieving INCI status is more than a mere formality; it confirms that Porton Advanced's stem cell exosomes comply with international safety, quality, and regulatory standards. This compliance not only alleviates regulatory hurdles for brands looking to integrate these ingredients into their products but also represents a significant milestone in Porton Advanced's strategic shift to expand its Contract Development and Manufacturing Organization (CDMO) services across diverse applications, particularly in the realm of cosmetic materials.

Porton Advanced has built a strong manufacturing framework dedicated to stem cell exosomes, drawing from its expertise in the cell and gene therapy sector. This encompasses stringent quality control measures and advanced manufacturing systems aimed at guaranteeing exosomes that are high in purity, activity, and stability. The company’s production capabilities are a result of its commitment to Good Manufacturing Practices (GMP), ensuring that the exosome products meet the highest standards.

Manufacturing Capabilities

Porton Advanced boasts a versatile manufacturing platform designed specifically for exosome production, including:

• - Flexible Cell Culture Systems: Capability to support multiple cell lines such as HEK293, MSC, K562, and IPSC, enhancing research versatility.
• - Scalable and Robust Processes: System scalability ranging from 2L to 50L bioreactors, enabling a smooth transition from research and development (R&D) to commercial deployment.
• - High Yield Production: Final exosome product concentration stands at ≥ 1E+11 particles/mL, indicating remarkable efficiency in production.
• - Rapid Delivery: Availability of GMP-grade exosomes within a one-month timeframe, ensuring quick market access.
• - Stringent Quality Control: Execution of extensive quality checks for identity, purity, potency, and safety to ensure consistency across batches.

Future Directions

With these advancements, Porton Advanced is set to continue pioneering the application of exosome technology within regenerative aesthetics. This includes providing integrated services to global partners that range from customizing raw materials to the development of formulations tailored for the cosmetic sector, propelling both innovation and usability.

About Porton Advanced

Porton Advanced Solutions is a prominent subsidiary of Porton Pharma Solutions, a leading CDMO with headquarters located in Cranbury, New Jersey, and two GMP facilities based in Suzhou, China. The company excels at offering comprehensive CDMO services for Advanced Therapy Medicinal Products (ATMPs).

The provided services encompass all stages of drug development—from cell banking and process analytics method development to cGMP production and final product filling. Porton Advanced is also recognized for its specialization in diverse service platforms, which involve plasmids, viral vectors, cell therapy, and nucleic acid therapies. The company’s state-of-the-art facilities cover an expansive 215,000 square feet and include 10 GMP-compliant production lines for viral vectors alongside multiple cleanroom environments.

Having successfully facilitated numerous global Investigational New Drug (IND) approvals from regulatory bodies like the NMPA and FDA, Porton Advanced is steadfast in its commitment to a customer-centric approach. By delivering exceptional end-to-end CDMO services, the company aims to ensure that effective therapies reach the public swiftly and efficiently.